TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $7.91 billion. The enterprise value is $8.15 billion.

Market Cap	7.91B
Enterprise Value	8.15B

Important Dates

The next estimated earnings date is Monday, August 3, 2026, before market open.

Earnings Date	Aug 3, 2026
Ex-Dividend Date	n/a

Share Statistics

TG Therapeutics has 141.72 million shares outstanding. The number of shares has decreased by -2.27% in one year.

Current Share Class	141.72M
Shares Outstanding	141.72M
Shares Change (YoY)	-2.27%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	4.63%
Owned by Institutions (%)	78.37%
Float	135.10M

Valuation Ratios

The trailing PE ratio is 19.45 and the forward PE ratio is 31.83. TG Therapeutics's PEG ratio is 2.11.

PE Ratio	19.45
Forward PE	31.83
PS Ratio	11.30
Forward PS	7.79
PB Ratio	13.57
P/TBV Ratio	13.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	2.11

Financial Ratio History

Enterprise Valuation

EV / Earnings	17.65
EV / Sales	11.64
EV / EBITDA	54.50
EV / EBIT	54.53
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.81, with a Debt / Equity ratio of 1.29.

Current Ratio	5.81
Quick Ratio	4.84
Debt / Equity	1.29
Debt / EBITDA	4.97
Debt / FCF	n/a
Interest Coverage	5.41

Financial Efficiency

Return on equity (ROE) is 112.60% and return on invested capital (ROIC) is 18.89%.

Return on Equity (ROE)	112.60%
Return on Assets (ROA)	8.55%
Return on Invested Capital (ROIC)	18.89%
Return on Capital Employed (ROCE)	11.14%
Weighted Average Cost of Capital (WACC)	12.54%
Revenue Per Employee	$1.76M
Profits Per Employee	$1.16M
Employee Count	399
Asset Turnover	0.64
Inventory Turnover	0.83

Taxes

Income Tax	-339.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +49.84% in the last 52 weeks. The beta is 1.67, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.67
52-Week Price Change	+49.84%
50-Day Moving Average	41.74
200-Day Moving Average	34.21
Relative Strength Index (RSI)	82.87
Average Volume (20 Days)	3,034,448

Short Selling Information

The latest short interest is 28.18 million, so 19.89% of the outstanding shares have been sold short.

Short Interest	28.18M
Short Previous Month	28.11M
Short % of Shares Out	19.89%
Short % of Float	20.86%
Short Ratio (days to cover)	13.49

Income Statement

In the last 12 months, TG Therapeutics had revenue of $700.35 million and earned $461.90 million in profits. Earnings per share was $2.87.

Revenue	700.35M
Gross Profit	581.67M
Operating Income	149.50M
Pretax Income	122.29M
Net Income	461.90M
EBITDA	149.58M
EBIT	149.50M
Earnings Per Share (EPS)	$2.87

Full Income Statement

Balance Sheet

The company has $514.43 million in cash and $753.56 million in debt, giving a net cash position of -$239.13 million or -$1.69 per share.

Cash & Cash Equivalents	514.43M
Total Debt	753.56M
Net Cash	-239.13M
Net Cash Per Share	-$1.69
Equity (Book Value)	583.13M
Book Value Per Share	4.11
Working Capital	899.86M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$13.95 million and capital expenditures -$240,000, giving a free cash flow of -$14.19 million.

Operating Cash Flow	-13.95M
Capital Expenditures	-240,000
Depreciation & Amortization	83,000
Net Borrowing	492.66M
Free Cash Flow	-14.19M
FCF Per Share	-$0.10

Full Cash Flow Statement

Margins

Gross margin is 83.05%, with operating and profit margins of 21.35% and 65.95%.

Gross Margin	83.05%
Operating Margin	21.35%
Pretax Margin	17.46%
Profit Margin	65.95%
EBITDA Margin	21.36%
EBIT Margin	21.35%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.27%
Shareholder Yield	2.27%
Earnings Yield	5.84%
FCF Yield	-0.18%

Analyst Forecast

The average price target for TG Therapeutics is $51.71, which is -7.38% lower than the current price. The consensus rating is "Buy".

Price Target	$51.71
Price Target Difference	-7.38%
Analyst Consensus	Buy
Analyst Count	9
Revenue Growth Forecast (3Y)	36.65%
EPS Growth Forecast (3Y)	7.12%

Stock Forecasts

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.

Last Split Date	Apr 30, 2012
Split Type	Reverse
Split Ratio	1:56.25

Scores

TG Therapeutics has an Altman Z-Score of 3.61 and a Piotroski F-Score of 3.

Altman Z-Score	3.61
Piotroski F-Score	3